Comparative Pharmacology
Head-to-head clinical analysis: BUTOCONAZOLE NITRATE versus SPORANOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTOCONAZOLE NITRATE versus SPORANOX.
BUTOCONAZOLE NITRATE vs SPORANOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Inhibits fungal cytochrome P450 (CYP450)-dependent lanosterol 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Intravaginal administration: 100 mg (one applicatorful of 2% cream) once daily for 3 days; or 100 mg (one suppository) once daily for 3 days; or 5 g (one applicatorful of 4% cream) as a single dose.
200 mg orally twice daily for 3-7 days; for onychomycosis: 200 mg orally once daily for 12 weeks.
None Documented
None Documented
Terminal half-life is approximately 21–24 hours, supporting once-daily or twice-weekly dosing for vaginal candidiasis.
The terminal elimination half-life of itraconazole ranges from 21 to 35 hours for single doses, increasing to approximately 34 to 42 hours at steady state. The half-life of the active metabolite, hydroxyitraconazole, is similar. This long half-life allows for once-daily or twice-daily dosing in most indications.
Primarily hepatic metabolism with <5% excreted unchanged in urine; fecal elimination accounts for ~30% of metabolites.
Itraconazole is extensively metabolized in the liver via CYP3A4 to active metabolites, including hydroxyitraconazole. The parent drug and metabolites are primarily excreted in feces (approximately 54%) and urine (approximately 35%), with less than 1% of the dose excreted unchanged in urine.
Category A/B
Category C
Antifungal
Antifungal